×

Method of treating cancer using kinase inhibitors

  • US 7,384,940 B2
  • Filed: 06/04/2003
  • Issued: 06/10/2008
  • Est. Priority Date: 06/05/2002
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method for treating a cancer that expresses functional epidermal growth factor receptors (EGFRs) in a patient resistant or non-responsive to a daily dose of EGFR-tyrosine kinase inhibitor selected from the group consisting of gefitinib and erlotinib, comprising:

  • providing a resistance-surmounting quantity of a kinase inhibitor; and

    administering the resistance-surmounting quantity of the kinase inhibitor to the patient at a time interval selected from the group consisting of once per week and twice per week,wherein the kinase inhibitor is selected from the group consisting of gefitinib or a pharmaceutically acceptable salt thereof, the resistance-surmounting quantity of the kinase inhibitor is at least 500 mg of the kinase inhibitor and the cancer is a type of cancer selected from the group consisting of prostate cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, ovarian cancer, and a glioblastoma tumor.

View all claims
  • 4 Assignments
Timeline View
Assignment View
    ×
    ×